State of Wisconsin Investment Board increased its position in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) by 53.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 43,082 shares of the biopharmaceutical company’s stock after buying an additional 15,082 shares during the quarter. State of Wisconsin Investment Board owned 0.09% of Clovis Oncology worth $3,550,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Phocas Financial Corp. bought a new position in shares of Clovis Oncology during the second quarter worth about $112,000. Advisors Asset Management Inc. grew its holdings in shares of Clovis Oncology by 160.7% during the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,168 shares in the last quarter. Legato Capital Management LLC bought a new position in shares of Clovis Oncology during the second quarter worth about $220,000. Bank of Montreal Can grew its holdings in shares of Clovis Oncology by 284.9% during the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 2,000 shares in the last quarter. Finally, Stevens Capital Management LP bought a new position in shares of Clovis Oncology during the second quarter worth about $257,000.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $63.70, for a total transaction of $191,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 9,000 shares of company stock valued at $653,220 over the last quarter. 12.50% of the stock is currently owned by corporate insiders.
A number of research firms recently issued reports on CLVS. Leerink Swann reiterated an “outperform” rating and set a $90.00 price objective (down from $107.00) on shares of Clovis Oncology in a report on Wednesday, November 15th. Stifel Nicolaus reiterated a “buy” rating and set a $125.00 price objective on shares of Clovis Oncology in a report on Friday, November 3rd. Morgan Stanley decreased their price objective on Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Barclays PLC began coverage on Clovis Oncology in a report on Monday, October 23rd. They set an “overweight” rating and a $105.00 price objective for the company. Finally, Zacks Investment Research upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a report on Tuesday, October 17th. Eight equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $86.15.
Clovis Oncology, Inc. (CLVS) opened at $61.17 on Wednesday. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94. Clovis Oncology, Inc. has a one year low of $33.23 and a one year high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. The business had revenue of $16.81 million for the quarter, compared to the consensus estimate of $21.12 million. During the same quarter in the prior year, the firm posted ($1.70) earnings per share. research analysts predict that Clovis Oncology, Inc. will post -7.63 earnings per share for the current fiscal year.
WARNING: “State of Wisconsin Investment Board Boosts Position in Clovis Oncology, Inc. (CLVS)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/11/22/state-of-wisconsin-investment-board-boosts-position-in-clovis-oncology-inc-clvs.html.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.